US EditionPublished • loading... • Updated
Japan Approves Emergency Contraceptive Pill for over-the-Counter Sales
Norlevo can now be sold without prescription or age restrictions, improving access after public support and concerns over prescription barriers for younger women and victims.
- On Monday, October 20, Japan's health ministry and ASKA Pharmaceutical said Norlevo obtained regulatory approval for over-the-counter sale, the first emergency contraceptive pill approved without a prescription in Japan.
- Discussions that began in 2017 culminated when a health ministry panel in August this year approved OTC sales after a small pilot at 145 pharmacies, under 0.2% of outlets.
- Norlevo is most effective within 72 hours with 80% efficacy, and during the 2023 trial pricing ranged from 7,000 to 9,000 yen .
- The drug is expected to reach shelves as early as this fiscal year, with no age limit or parental consent required, and ASKA Pharmaceutical said it would `empower Japanese women in the area of reproductive health`.
- The idea of OTC sale traces back to 2017 health ministry discussion, with public consultation showing overwhelming support, though officials and rights groups debated potential misuse and restrictions.
Insights by Ground AI
17 Articles
17 Articles
Japan approved for the first time the sale of an emergency contraceptive pill, announced the drug manufacturer, which will allow women in the country to obtain it without medical prescription, says BBC.
·Romania
Read Full Article
Japan approved, for the first time in its history, the sale of an emergency contraceptive pill, announced its manufacturer, which will allow women in the country to take the medicine without prescription...
·Romania
Read Full Article
Japan Approves Sale Of First Over-The-Counter Emergency Contraceptive Pill
Japan has given regulatory approval for an over-the-counter contraceptive pill, its manufacturer said on Monday, the first time the socially conservative country has greenlighted so-called "morning-after" medication without a prescription.
·New Delhi, India
Read Full Article
Coverage Details
Total News Sources17
Leaning Left2Leaning Right2Center3Last UpdatedBias Distribution43% Center
Bias Distribution
- 43% of the sources are Center
43% Center
L 29%
C 43%
R 28%
Factuality
To view factuality data please Upgrade to Premium
